500 Pembrolizumab (MK-3475) for PD-L1-positive squamous cell carcinoma (SCC) of the anal canal: Preliminary safety and efficacy results from KEYNOTE-028. Issue 3 (September 2015) - Ott, P.A.; Piha-Paul, S.A.; Munster, P.; Pishvaian, M.J.; Van Brummelen, E.; Cohen, R.; Gomez-Roca, C.; Ejadi, S.; Stein, M.; Chan, E.; Simonelli, M.; Morosky, A.; et al.